🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
1.120
-0.030 (-2.61%)
At close: Nov 19, 2026, 4:00 PM EST
1.130
+0.010 (0.89%)
After-hours: Nov 19, 2026, 7:30 PM EST

Company Description

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.

The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta, Inc.
Nkarta logo
CountryUnited States
Founded2015
IPO DateJul 10, 2020
IndustryBiotechnology
SectorHealthcare
Employees103
CEOPaul Hastings

Contact Details

Address:
1150 Veterans Boulevard
South San Francisco, California 94080
United States
Phone925 407 1049
Websitenkartatx.com

Stock Details

Ticker SymbolNKTX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$18.00
CIK Code1787400
CUSIP Number65487U108
ISIN NumberUS65487U1088
Employer ID47-4515206
SIC Code2834

Key Executives

NamePosition
Paul J. HastingsChief Executive Officer and Director
Dr. Nadir Mahmood Ph.D.President and Principal Accounting and Financial Officer
Dr. Shawn Rose M.D., Ph.D.Chief Medical Officer and Head of Research and Development

Latest SEC Filings

DateTypeTitle
Nov 9, 20268-KCurrent Report
Nov 6, 20268-KCurrent Report
Nov 5, 202610-QQuarterly Report
Nov 5, 20268-KCurrent Report
Aug 10, 202610-QQuarterly Report
Aug 10, 20268-KCurrent Report
Jun 11, 20268-KCurrent Report
May 19, 2026SCHEDULE 13D/AFiling
May 12, 202610-QQuarterly Report
May 12, 20268-KCurrent Report
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides